This animal study tested orally administered Dihexa, an angiotensin IV analog that crosses the blood-brain barrier, in the APP/PS1 mouse model of Alzheimer’s-type pathology. Dihexa improved performance on spatial learning and memory testing, increased neuronal cell counts and synaptic protein expression, and reduced markers of neuroinflammation. The observed effects tracked with activation of the PI3K/AKT signaling pathway and were reversed when that pathway was blocked. This is animal model evidence and does not establish efficacy or safety in human populations.
For your business
Animal data suggest oral Dihexa may support cognition via PI3K/AKT; human translation remains unestablished.